Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.

Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.

Show other versions (1)

<p>We examined the prognostic value of programmed cell death-1 (PD-1) and its ligand (PD-L1) together with CD8+ tumor-infiltrating lymphocytes (TILs) and FOXP3+ Tregs in resectable pancreatic ductal adenocarcinoma (PDAC) samples treated with adjuvant chemotherapy. Whole-mount FFPE tiss...

Full description

Bibliographic Details
Main Authors:	Diana, A, Wang, L, D'Costa, Z, Allen, P, Azad, A, Silva, M, Soonawalla, Z, Liu, S, McKenna, W, Muschel, R, Fokas, E
Format:	Journal article
Language:	English
Published:	Impact Journals 2016

Similar Items

Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.
by: Diana, A, et al.
Published: (2016)

The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma
by: Wang, L, et al.
Published: (2015)

PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy
by: Dushek, O, et al.
Published: (2016)

Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma
by: Tina Daunke, et al.
Published: (2023-06-01)

High expression of both desmoplastic stroma and epithelial to mesenchymal transition markers associate with shorter survival in pancreatic ductal adenocarcinoma
by: Damián Sánchez-Ramírez, et al.
Published: (2022-02-01)

Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic.
by: Fokas, E, et al.
Published: (2015)

Restored CD8+PD-1+ T Cells Facilitate the Response to Anti-PD-1 for Patients With Pancreatic Ductal Adenocarcinoma
by: Qian Zhu, et al.
Published: (2022-04-01)

Immune features of the peritumoral stroma in pancreatic ductal adenocarcinoma
by: Azaz Ahmed, et al.
Published: (2022-09-01)

Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma.
by: Ole Helm, et al.
Published: (2014-01-01)

Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma
by: Adam L. Burrack, et al.
Published: (2019-08-01)

Is hyaluronan deposition in the stroma of pancreatic ductal adenocarcinoma of prognostic significance?
by: Florian Gebauer, et al.
Published: (2017-01-01)

PD‐L1 and PD‐L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules
by: Yue Zhang, et al.
Published: (2022-05-01)

The T-cell architecture of pancreatic ductal adenocarcinoma
by: Sivakumar, S, et al.
Published: (2019)

The T cell architecture of pancreatic ductal adenocarcinoma
by: Sivakumar, S, et al.
Published: (2019)

A Comprehensive Transcriptional Signature in Pancreatic Ductal Adenocarcinoma Reveals New Insights into the Immune and Desmoplastic Microenvironments
by: Irene Pérez-Díez, et al.
Published: (2023-05-01)

Soluble Compounds Released by Hypoxic Stroma Confer Invasive Properties to Pancreatic Ductal Adenocarcinoma
by: Dajia Liu, et al.
Published: (2020-10-01)

The tumor–stroma ratio and the immune microenvironment improve the prognostic prediction of pancreatic ductal adenocarcinoma
by: Mei Lu, et al.
Published: (2023-07-01)

Bispecific immune molecule PD1-IL2v: a new therapeutic strategy for pancreatic ductal adenocarcinoma
by: Yuan Gao, et al.
Published: (2023-10-01)

Human papilloma virus load and PD-1/PD-L1, CD8+ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy
by: Panagiotis Balermpas, et al.
Published: (2017-03-01)

The Desmoplastic Stroma of Pancreatic Cancer: Multilayered Levels of Heterogeneity, Clinical Significance, and Therapeutic Opportunities
by: Yohei Masugi
Published: (2022-07-01)

Case report: Ductal eccrine adenocarcinoma with fibromyxoid stroma
by: Kyle Mitts, DO, et al.
Published: (2017-09-01)

The PD-L1 Expression and Tumor-Infiltrating Immune Cells Predict an Unfavorable Prognosis in Pancreatic Ductal Adenocarcinoma and Adenosquamous Carcinoma
by: Zhiwei Zhang, et al.
Published: (2023-02-01)

Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma
by: Bryn Golesworthy, et al.
Published: (2022-04-01)

PD-L1 in pancreatic ductal adenocarcinoma: a retrospective analysis of 373 Chinese patients using an in vitro diagnostic assay
by: Xiaolong Liang, et al.
Published: (2018-01-01)

Tumor Stroma Area and Other Prognostic Factors in Pancreatic Ductal Adenocarcinoma Patients Submitted to Surgery
by: Maria João Amaral, et al.
Published: (2023-02-01)

Genomic Landscape in Neoplasm-Like Stroma Reveals Distinct Prognostic Subtypes of Pancreatic Ductal Adenocarcinoma
by: Jiahong Jiang, et al.
Published: (2021-10-01)

3D heterospecies spheroids of pancreatic stroma and cancer cells demonstrate key phenotypes of pancreatic ductal adenocarcinoma
by: Xinyuan Liu, et al.
Published: (2021-07-01)

Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma
by: Gokce Askan, et al.
Published: (2021-04-01)

Evaluation of MMR Status and PD-L1 Expression Using Specimens Obtained by EUS-FNB in Patients with Pancreatic Ductal Adenocarcinoma (PDAC)
by: Alina Constantin, et al.
Published: (2022-01-01)

Hepatic myofibroblasts exert immunosuppressive effects independent of the immune checkpoint regulator PD-L1 in liver metastasis of pancreatic ductal adenocarcinoma
by: Silje Beckinger, et al.
Published: (2023-05-01)

Diffusion Kurtosis Imaging—A Superior Approach to Assess Tumor–Stroma Ratio in Pancreatic Ductal Adenocarcinoma
by: Philipp Mayer, et al.
Published: (2020-06-01)

CT Radiomics and Machine-Learning Models for Predicting Tumor-Stroma Ratio in Patients With Pancreatic Ductal Adenocarcinoma
by: Yinghao Meng, et al.
Published: (2021-11-01)

Programmed Death-Ligand 1 (PD-L1) Expression Is Induced by Insulin in Pancreatic Ductal Adenocarcinoma Cells Pointing to Its Role in Immune Checkpoint Control
by: Steffen M. Heckl, et al.
Published: (2021-06-01)

PD-1<sup>+</sup>CD8<sup>+</sup> T Cells Proximal to PD-L1<sup>+</sup>CD68<sup>+</sup> Macrophages Are Associated with Poor Prognosis in Pancreatic Ductal Adenocarcinoma Patients
by: Xiaobao Yang, et al.
Published: (2023-02-01)

Gemcitabine-induced TIMP1 attenuates therapy response and promotes tumor growth and liver metastasis in pancreatic cancer
by: D'Costa, Z, et al.
Published: (2017)

A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma
by: Yiyin Zhang, et al.
Published: (2019-08-01)

Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma
by: Benjamin Bian, et al.
Published: (2019-04-01)

Tumor–stroma ratio predicts prognosis and PD-L1 expression in hepatocellular carcinoma
by: Dong Wang, et al.
Published: (2023-05-01)

Feasibility and effectiveness of automatic deep learning network and radiomics models for differentiating tumor stroma ratio in pancreatic ductal adenocarcinoma
by: Hongfan Liao, et al.
Published: (2023-12-01)

PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes.
by: Bin Liu, et al.
Published: (2018-01-01)